ELOVL1 Activators
ELOVL1 (Elongation of Very Long-Chain Fatty Acids Protein 1) activators belong to a specialized class of chemical compounds known for their capacity to modulate the expression and activity of the ELOVL1 enzyme. ELOVL1 is a critical enzyme involved in the elongation of very long-chain fatty acids (VLCFAs) within cells. VLCFAs are essential lipid components found in various cell membranes and play pivotal roles in numerous physiological processes, including maintaining membrane fluidity and function. These activators are meticulously designed to interact with regulatory elements associated with the ELOVL1 gene, potentially influencing its expression and affecting the enzymatic elongation of fatty acids. Mechanistically, the actions of ELOVL1 activators can involve binding to specific DNA sequences within the ELOVL1 gene promoter or enhancer regions, thereby promoting or enhancing ELOVL1 gene expression.
Research on ELOVL1 activators is fundamental for advancing our understanding of lipid metabolism and the regulation of VLCFA production within cells. Scientists in this field primarily focus on elucidating the precise molecular mechanisms by which these compounds impact ELOVL1's function and their downstream effects on cellular lipid composition and membrane properties. ELOVL1 is crucial for maintaining the integrity and functionality of cellular membranes. Therefore, understanding the role of ELOVL1 activators contributes to our broader knowledge of lipid biology and the intricate processes governing lipid homeostasis, shedding light on the molecular basis of membrane function. These activators serve as invaluable tools for researchers seeking to investigate the molecular cues and regulatory mechanisms governing lipid metabolism, ultimately deepening our understanding of the complex world of cellular lipid biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
25-Hydroxycholesterol | 2140-46-7 | sc-214091B sc-214091 sc-214091A sc-214091C | 5 mg 10 mg 25 mg 100 mg | $53.00 $91.00 $169.00 $474.00 | 8 | |
A lipid regulator; might influence ELOVL1 expression through SREBP (sterol regulatory element-binding proteins) mediated signaling. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
HMG-CoA reductase inhibitor; might indirectly influence ELOVL1 by altering lipid synthesis pathways. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
HMG-CoA reductase inhibitor; could potentially affect ELOVL1 through lipid metabolism regulation. | ||||||
Docosa-4Z,7Z,10Z,13Z,16Z,19Z-hexaenoic Acid (22:6, n-3) | 6217-54-5 | sc-200768 sc-200768A sc-200768B sc-200768C sc-200768D | 100 mg 1 g 10 g 50 g 100 g | $94.00 $210.00 $1779.00 $8021.00 $16657.00 | 11 | |
Might upregulate ELOVL1 to facilitate the synthesis of necessary lipids. | ||||||
4-Phenylbutyric acid | 1821-12-1 | sc-232961 sc-232961A sc-232961B | 25 g 100 g 500 g | $53.00 $136.00 $418.00 | 10 | |
Histone deacetylase inhibitor; could potentially influence ELOVL1 expression through epigenetic mechanisms. | ||||||
Troglitazone | 97322-87-7 | sc-200904 sc-200904B sc-200904A | 5 mg 10 mg 25 mg | $110.00 $204.00 $435.00 | 9 | |
PPARγ agonist; may influence ELOVL1 expression through PPAR signaling. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
May influence ELOVL1 indirectly due to its role in cholesterol synthesis inhibition. | ||||||
Fluvastatin | 93957-54-1 | sc-279169 | 50 mg | $250.00 | ||
Its effects on cholesterol synthesis might influence ELOVL1 expression indirectly. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Could potentially influence ELOVL1 due to its role in cholesterol synthesis inhibition. | ||||||